Omeros Corp(OMER) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 11.33 | EPS (ttm) | 1.44 | Insider Own | 4.29% | Shs Outstand | 72.1M | Perf Week | -0.37% |
| Market Cap | 1.18B | Forward P/E | 15.41 | EPS next Y | 28.15% | Insider Trans | -3.82% | Shs Float | 69.3M | Perf Month | -18.87% |
| Enterprise Value | 1.34B | PEG | - | EPS next Q | 0.02 | Inst Own | 49.9% | Short Float | 16.43% | Perf Quarter | 44.41% |
| Income | 0.12B | P/S | 30.69 | EPS this Y | 1750% | Inst Trans | 8.59% | Short Ratio | 6.66 | Perf Half Y | 10.52% |
| Sales | 0.04B | P/B | - | EPS next 5Y | - | ROA | 47.82% | Short Interest | 11.38M | Perf YTD | -5.15% |
| Book/sh | -0.71 | P/C | 8.94 | EPS past 3/5Y | - 53.45% | ROE | - | 52W High | -23.3% ($21.24) | Perf Year | 115.76% |
| Cash/sh | 1.82 | P/FCF | - | Sales past 3/5Y | - | ROIC | 67.05% | 52W Low | 161.06% ($6.24) | Perf 3Y | 1401.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 181.47% | Gross Margin | 94.02% | Volatility(W/M) | 3.54% 4.24% | Perf 5Y | 155.73% |
| Dividend TTM | - | EV/Sales | 34.99 | Sales Y/Y TTM | - | Oper. Margin | -189.53% | ATR (14) | 0.84 | Perf 10Y | 99.63% |
| Dividend Ex-Date | - | Quick Ratio | 1.94 | EPS Q/Q | 134.01% | Profit Margin | 324.88% | RSI (14) | 38.57 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.95 | Sales Q/Q | - | SMA20 | -9.82% ($18.06) | Beta | 2.98 | Target Price | $36.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | -11.93% ($18.5) | Rel Volume | 0.43 | Prev Close | $16.57 |
| Employees | 175 | LT Debt/Eq | - | EPS/Sales Surpr. | 155.91% 124.79% | SMA200 | 21.77% ($13.38) | Avg Volume(3M) | 1.71M | Price | $16.29 |
| IPO | 2009/10/8 | Option/Short | Yes/Yes | Trades | 5392 | Volume | 741,409 | Change | -1.69% |
🧬 Omeros (OMER) is an innovative biopharmaceutical company targeting immune and complement-mediated diseases. Centered on a drug platform that inhibits MASP-2, a key enzyme in the lectin pathway, it focuses on developing and commercializing a pipeline of small-molecule and protein therapeutics aimed at both rare diseases and large indications.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
OMER has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1750.0% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,541. Peers typically go for $1,554.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +155.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 49.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PBE Invesco Biotechnology & Genome ETF 0.03% 
BBP Virtus Biotech ETF 0.02% 
XPH State Street SPDR S&P Pharmaceuticals ETF 0.01% 
PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF 0.01% 
BBC Virtus Biotech Clinical Trials ETF 0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
ACSI American Customer Satisfaction ETF 115M 
WNDR Corgi Travel & Leisure ETF - 
STYL Corgi Lifestyle Brands ETF - It ranks #145 of 594 in the industry
Based on market cap of $1B.
FAQ
What kind of company is OMER?
OMER belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OMER?
The market cap of OMER is approximately $1.2B, ranking 2,438 within its sector.
What is the P/E ratio of OMER?
OMER has a P/E ratio of approximately 11.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OMER?
OMER has recorded a 52-week high of $21.24 and a low of $6.24.
